Mohit Ahuja, MD
Nephrology · Flowood, MSNPI 1134339286
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $335,807 of the $426,916 with a category attached, or 78.7%. AstraZeneca accounts for 79.0% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2019 at $86,154 and has fallen 65.4% since, to $29,792 in 2025. Among nephrology clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 944 payments — averaging $452.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$337K
- Amgen$34K
- Boehringer Ingelheim$33K
- Akebia Therapeutics Inc$11K
- Otsuka America Pharmaceutical, Inc.$5K
- Lilly USA, LLC$2K
- plus $4K from 22 others
What the payments were for
- Consulting fees$8,8782%
- Speaking & faculty fees$335,80779%
- Travel & lodging$60,22914%
- Food & beverage$21,8115%
- Education$1920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 568 | $337,208 |
| Amgen(2 entities) | 93 | $33,774 |
| Boehringer Ingelheim | 44 | $33,189 |
| Akebia Therapeutics Inc | 44 | $11,156 |
| Otsuka America Pharmaceutical, Inc. | 46 | $5,230 |
| Lilly USA, LLC | 12 | $2,170 |
| Vifor Pharma, Inc. | 12 | $1,672 |
| Mallinckrodt Hospital Products Inc. | 20 | $550 |
| Fresenius USA Marketing, Inc. | 29 | $499 |
| Bayer | 12 | $216 |
| Aurinia Pharma U.S., Inc. | 8 | $170 |
| ANI Pharmaceuticals, Inc. | 9 | $169 |
| OPKO Pharmaceuticals, LLC | 10 | $146 |
| Calliditas Therapeutics US Inc. | 5 | $134 |
| Novartis | 5 | $125 |
| Ardelyx, Inc. | 6 | $118 |
| GSK | 5 | $106 |
| Vanda Pharmaceuticals Inc. | 5 | $90 |
| Scpharmaceuticals Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Travere Therapeutics, Inc. | 1 | $18 |
| Apellis Pharmaceuticals, Inc. | 1 | $16 |
| Baxter Healthcare | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $14 |
| Sanofi | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$426,916 in reported general payments places this provider in the 95th percentile of 105 nephrology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 30 | $97,659 |
| JardianceEmpagliflozin | 116 | $89,866 |
| FarxigaDapagliflozin Propanediol | 113 | $89,727 |
| VelphoroSucroferric Oxyhydroxide | 25 | $81,518 |
| AuryxiaFerric Citrate | 31 | $57,509 |
| RayaldeeCalcifediol | 14 | $16,583 |
| Febuxostat | 88 | $10,100 |
| LokelmaSodium Zirconium Cyclosilicate | 12 | $6,918 |
| Sevelamer Carbonate | 42 | $6,244 |
| Diltiazem 12hr ErDiltiazem Hcl | 16 | $3,484 |
| Nifedipine ErNifedipine | 77 | $2,809 |
| Calcium Acetate | 18 | $1,120 |
| Nebivolol Hcl | 11 | $1,071 |
| Midodrine Hcl | 14 | $1,022 |
| Hydralazine Hcl | 92 | $945 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $337,208 | $96,645125 claims |
| Boehringer IngelheimJardiance | $33,189 | $89,866116 claims |
| Fresenius USA Marketing, Inc.Velphoro | $499 | $81,51825 claims |
| Akebia Therapeutics IncAuryxia | $11,156 | $57,50931 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $146 | $16,58314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 105 nephrology providers in Mississippi.
Other nephrology in Flowood
- Steven WagnerFlowood$6K
- Francis PhillippiFlowood$6K
- Daphne BilbrewFlowood$6K
- Derrick TesseneerFlowood$5K
- Ami PatelFlowood$5K
- Karthikeyan VenkatachalamFlowood$5K
- Lee FergusonFlowood$4K
- Lindsey NorrisFlowood$4K
- Mark KleinFlowood$3K
- Naveen SandhuFlowood$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.